Literature DB >> 22222599

Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulin heavy variable gene: ontogenetic implications.

V Bikos1, N Darzentas, A Hadzidimitriou, Z Davis, S Hockley, A Traverse-Glehen, P Algara, A Santoro, D Gonzalez, M Mollejo, A Dagklis, F Gangemi, D S Bosler, G Bourikas, A Anagnostopoulos, A Tsaftaris, E Iannitto, M Ponzoni, P Felman, F Berger, C Belessi, P Ghia, T Papadaki, A Dogan, M Degano, E Matutes, M A Piris, D Oscier, K Stamatopoulos.   

Abstract

We performed an immunogenetic analysis of 345 IGHV-IGHD-IGHJ rearrangements from 337 cases with primary splenic small B-cell lymphomas of marginal-zone origin. Three immunoglobulin (IG) heavy variable (IGHV) genes accounted for 45.8% of the cases (IGHV1-2, 24.9%; IGHV4-34, 12.8%; IGHV3-23, 8.1%). Particularly for the IGHV1-2 gene, strong biases were evident regarding utilization of different alleles, with 79/86 rearrangements (92%) using allele (*)04. Among cases more stringently classified as splenic marginal-zone lymphoma (SMZL) thanks to the availability of splenic histopathological specimens, the frequency of IGHV1-2(*)04 peaked at 31%. The IGHV1-2(*)04 rearrangements carried significantly longer complementarity-determining region-3 (CDR3) than all other cases and showed biased IGHD gene usage, leading to CDR3s with common motifs. The great majority of analyzed rearrangements (299/345, 86.7%) carried IGHV genes with some impact of somatic hypermutation, from minimal to pronounced. Noticeably, 75/79 (95%) IGHV1-2(*)04 rearrangements were mutated; however, they mostly (56/75 cases; 74.6%) carried few mutations (97-99.9% germline identity) of conservative nature and restricted distribution. These distinctive features of the IG receptors indicate selection by (super)antigenic element(s) in the pathogenesis of SMZL. Furthermore, they raise the possibility that certain SMZL subtypes could derive from progenitor populations adapted to particular antigenic challenges through selection of VH domain specificities, in particular the IGHV1-2(*)04 allele.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22222599     DOI: 10.1038/leu.2012.3

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  33 in total

1.  Persistent polyclonal B-cell lymphocytosis: extensively proliferated CD27+IgM+IgD+ memory B cells with a distinctive immunophenotype.

Authors:  M A Berkowska; C Grosserichter-Wagener; H J Adriaansen; D de Ridder; K P Mirani-Oostdijk; H J Agteresch; S Böttcher; A Orfao; J J M van Dongen; M C van Zelm
Journal:  Leukemia       Date:  2014-02-19       Impact factor: 11.528

Review 2.  Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms.

Authors:  Arantza Onaindia; L Jeffrey Medeiros; Keyur P Patel
Journal:  Mod Pathol       Date:  2017-06-30       Impact factor: 7.842

3.  Toll-like receptor stimulation in splenic marginal zone lymphoma can modulate cell signaling, activation and proliferation.

Authors:  Eleonora Fonte; Andreas Agathangelidis; Daniele Reverberi; Stavroula Ntoufa; Lydia Scarfò; Pamela Ranghetti; Giovanna Cutrona; Alessandra Tedeschi; Aliki Xochelli; Federico Caligaris-Cappio; Maurilio Ponzoni; Chrysoula Belessi; Zadie Davis; Miguel A Piris; David Oscier; Paolo Ghia; Kostas Stamatopoulos; Marta Muzio
Journal:  Haematologica       Date:  2015-08-20       Impact factor: 9.941

4.  IgM peak independently predicts treatment-free survival in chronic lymphocytic leukemia and correlates with accumulation of adverse oncogenetic events.

Authors:  D Rizzo; J Chauzeix; F Trimoreau; J B Woillard; F Genevieve; A Bouvier; J Labrousse; C Poli; E Guerin; N Dmytruk; L Remenieras; J Feuillard; N Gachard
Journal:  Leukemia       Date:  2014-06-19       Impact factor: 11.528

5.  A restricted IGHV gene repertoire in splenic marginal zone lymphoma is associated with autoimmune disorders.

Authors:  Gabriel Brisou; Aurélie Verney; Thomas Wenner; Lucile Baseggio; Pascale Felman; Evelyne Callet-Bauchu; Bertrand Coiffier; Françoise Berger; Gilles Salles; Alexandra Traverse-Glehen
Journal:  Haematologica       Date:  2014-07-04       Impact factor: 9.941

6.  Molecular and cytogenetic characterization of expanded B-cell clones from multiclonal versus monoclonal B-cell chronic lymphoproliferative disorders.

Authors:  Ana Henriques; Arancha Rodríguez-Caballero; Ignacio Criado; Anton W Langerak; Wendy G Nieto; Quentin Lécrevisse; Marcos González; Emília Cortesão; Artur Paiva; Julia Almeida; Alberto Orfao
Journal:  Haematologica       Date:  2014-01-31       Impact factor: 9.941

7.  Langerhans cell sarcoma following marginal zone lymphoma: expanding the knowledge on mature B cell plasticity.

Authors:  Maria Raffaella Ambrosio; Giulia De Falco; Bruno Jim Rocca; Aurora Barone; Teresa Amato; Cristiana Bellan; Stefano Lazzi; Lorenzo Leoncini
Journal:  Virchows Arch       Date:  2015-08-19       Impact factor: 4.064

8.  Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling.

Authors:  Marcus Dühren-von Minden; Rudolf Übelhart; Dunja Schneider; Thomas Wossning; Martina P Bach; Maike Buchner; Daniel Hofmann; Elena Surova; Marie Follo; Fabian Köhler; Hedda Wardemann; Katja Zirlik; Hendrik Veelken; Hassan Jumaa
Journal:  Nature       Date:  2012-09-13       Impact factor: 49.962

9.  Primary vitreoretinal lymphomas display a remarkably restricted immunoglobulin gene repertoire.

Authors:  Nabila Belhouachi; Aliki Xochelli; Myriam Boudjoghra; Claude Lesty; Nathalie Cassoux; Christine Fardeau; Thi Ha Chau Tran; Sylvain Choquet; Bishnu Sarker; Caroline Houillier; Agusti Alentorn; Phuc LeHoang; Carole Soussain; Valerie Touitou; Helene Merle-Beral; Khe Hoang-Xuan; Bahram Bodaghi; Kostas Stamatopoulos; Frederic Davi
Journal:  Blood Adv       Date:  2020-04-14

10.  Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features.

Authors:  Alba Navarro; Guillem Clot; Cristina Royo; Pedro Jares; Anastasia Hadzidimitriou; Andreas Agathangelidis; Vasilis Bikos; Nikos Darzentas; Theodora Papadaki; Itziar Salaverria; Magda Pinyol; Xavier Puig; Jara Palomero; Maria Carmela Vegliante; Virgina Amador; Alejandra Martinez-Trillos; Lenka Stefancikova; Adrian Wiestner; Wyndham Wilson; Christiane Pott; Maria Jose Calasanz; Nicola Trim; Wendy Erber; Birgitta Sander; German Ott; Andreas Rosenwald; Dolors Colomer; Eva Giné; Reiner Siebert; Armando Lopez-Guillermo; Kostas Stamatopoulos; Sílvia Beà; Elías Campo
Journal:  Cancer Res       Date:  2012-08-20       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.